<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344994</url>
  </required_header>
  <id_info>
    <org_study_id>gskswitch</org_study_id>
    <nct_id>NCT00344994</nct_id>
  </id_info>
  <brief_title>SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole</brief_title>
  <official_title>An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole&#xD;
      for patients switched from pramipexole to ropinirole in patients with moderate to severe&#xD;
      primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with&#xD;
      Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched&#xD;
      from one dopamine agonist to an equipotent dose of another.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND Dopamine agonists such as ropinirole (Requip) and pramipexole (Mirapex) are&#xD;
      effective treatments for Restless Legs Syndrome and Parkinson Disease. However, although the&#xD;
      safety and efficacy may be established, it is common for clinicians to switch between&#xD;
      therapies in order to seek optimal symptomatic relief for their patients. The best strategy&#xD;
      for switching from other dopamine agonists to Requip is currently undetermined. Currently,&#xD;
      ropinirole is the only medication indicated for the treatment of moderate to severe RLS.&#xD;
&#xD;
      Every patient will have an individual response to each dopamine agonist. Usually patients are&#xD;
      switched from one dopamine agonist to another due to the following factors:&#xD;
&#xD;
        -  Lack of response or loss of efficacy&#xD;
&#xD;
        -  Predictable and dose-related side effects&#xD;
&#xD;
        -  Ergot-associated adverse events (pulmonary fibrosis, cardiac valvulopathy, etc.)&#xD;
&#xD;
        -  Sleep events (sudden onset of sleep)&#xD;
&#xD;
        -  Peripheral edema&#xD;
&#xD;
        -  Patient co-morbidities&#xD;
&#xD;
      The lack of clinical data makes it difficult to recommend switching guidelines that are&#xD;
      suitable for all patients. It is therefore recommended that the switching regimen be based on&#xD;
      clinical judgment with individualization for each patient. Switching from one dopamine&#xD;
      agonist to another is dependent upon a number of factors including:&#xD;
&#xD;
        1. The currently prescribed dopamine agonist&#xD;
&#xD;
        2. The dose of the current dopamine agonist&#xD;
&#xD;
        3. Whether dopamine agonist is being administered as monotherapy or as adjunct therapy to&#xD;
           L-dopa&#xD;
&#xD;
        4. Individual patient response to both the current agonist and to the other dopamine&#xD;
           agonist (efficacy and tolerability)&#xD;
&#xD;
        5. Stage of the disease&#xD;
&#xD;
      In placebo-controlled, clinical trials for Requip, a protocol for switching patients to&#xD;
      Requip was not utilized. Patients were generally required to discontinue previous dopamine&#xD;
      agonist medications at least two weeks prior to baseline evaluation. Patients already on&#xD;
      dopamine agonists were discontinued according to the practices of the investigators.&#xD;
&#xD;
      Methods of switching that have been studied previously include:&#xD;
&#xD;
        1. Withdrawal of the current dopamine agonist according to the manufacturer's&#xD;
           recommendations followed by initiation of the other dopamine agonist based upon the&#xD;
           manufacturer's recommendations&#xD;
&#xD;
        2. An overnight switch with abrupt cessation of the current dopamine agonist followed by&#xD;
           initiation of an estimated equivalent dose of the other dopamine agonist&#xD;
&#xD;
        3. Gradual withdrawal of the current dopamine agonist with simultaneous upward titration of&#xD;
           the other dopamine agonist&#xD;
&#xD;
           STUDY DESIGN&#xD;
&#xD;
           SWITCH is a principal investigator-initiated, open-label study that is being conducted&#xD;
           at two sites, to include the Medical College of Georgia and the VA Medical Center&#xD;
           (VAMC). A total of 20 subjects will be enrolled at MCG/VAMC. Individuals who choose to&#xD;
           participate will have approximately three to four study visits over a four week time&#xD;
           period. Patients with moderate to severe primary Restless Legs Syndrome will be included&#xD;
           in the study. All RLS medications will be at a stable dose for at least 4 weeks prior to&#xD;
           enrollment. Patients will be switched overnight at the Baseline Visit at a ratio of&#xD;
           either 1:4 or 1:6 Mirapex (pramipexole) to Requip (ropinirole) per Conversion Table 1&#xD;
           below:&#xD;
&#xD;
           Table 1: Conversion Table&#xD;
&#xD;
           Pramipexole Dose Requip Dose (tablets)&#xD;
&#xD;
           1:4 conversion&#xD;
&#xD;
           0.25mg------------------ 1mg (1X1mg)&#xD;
&#xD;
           0.5mg ------------------ 2mg(1X2mg)&#xD;
&#xD;
           0.75mg-------------------3mg (1X 3mg)&#xD;
&#xD;
           1:6 Conversion&#xD;
&#xD;
           0.25mg------------------1.5mg (3X0.5mg)&#xD;
&#xD;
           0.5mg ------------------3mg (1X 3mg)&#xD;
&#xD;
           0.75mg------------------4mg (1X4mg)&#xD;
&#xD;
           At the baseline study visit, a signed and dated consent will first be obtained from the&#xD;
           subject. In addition, inclusion/exclusion criteria will be reviewed before the start of&#xD;
           any study procedures.&#xD;
&#xD;
           During the course of the study, some or all of the following procedures will be&#xD;
           performed, when patients come to the clinic for their study visit (Table 2):&#xD;
&#xD;
             -  Health and Medication Review: Ask patients to answer questions about their health,&#xD;
                medical history, and their medications. (All visits)&#xD;
&#xD;
             -  Mini-Mental State Examination: Patients will be asked a series of questions to&#xD;
                determine their mental status. (Visit 1)&#xD;
&#xD;
             -  CGI-S/CGI-I: (Visits 1, 2, and 4)&#xD;
&#xD;
             -  IRLS: (Visits 1, 2, and 4)&#xD;
&#xD;
             -  Epworth Sleepiness Scale: (Visits 1, 2, and 4)&#xD;
&#xD;
             -  ECG: An &quot;ECG&quot; or &quot;electrocardiogram&quot; is a test that measures the electrical&#xD;
                activity of the heart. (Visits 1, 2, and 4)&#xD;
&#xD;
             -  Blood Tests: The study staff will draw about 3 tablespoons. The study doctor will&#xD;
                use this blood for Hematology and Chemistry panel laboratory tests. (Visit 1)&#xD;
&#xD;
             -  Pregnancy Tests: If the patient is female and can have children, their blood (about&#xD;
                one extra tablespoon will be needed to perform this test) will be tested to see if&#xD;
                they are pregnant. Patients will be told if the test results are positive. The&#xD;
                results of the test must be negative in order for the patient to be in the study.&#xD;
                (Visit 1)&#xD;
&#xD;
             -  Neurological and Physical Exam: The study doctor will perform both a neurological&#xD;
                and a physical exam. (Visit 1)&#xD;
&#xD;
             -  Brief Physical Exam (Visits 2 and 4)&#xD;
&#xD;
             -  Concomitant Medication Review (All visits)&#xD;
&#xD;
             -  Blood Pressure, Pulse (Visits 1, 2, and 4)&#xD;
&#xD;
             -  Height (Visit 1)&#xD;
&#xD;
             -  Weight (Visit 1)&#xD;
&#xD;
             -  Study Drug: Give patients a supply of study drug and tell them how to take it.&#xD;
                Patients will be asked to bring back all unused study drug to each visit. (Visits&#xD;
                1, 2, and 4)&#xD;
&#xD;
             -  Drug Compliance (Visits 2, 3, and 4)&#xD;
&#xD;
             -  Adverse Event Review (Visits 2, 3, and 4)&#xD;
&#xD;
             -  Telephone Contact: The study doctor or study staff will call the patient to check&#xD;
                on his/her health and see how he/she is handling the study drug. If the study&#xD;
                doctor decides that the patient is doing well on the medication, Visit 3 could only&#xD;
                consist of a telephone contact to include a review of concomitant medications,&#xD;
                adverse events, and drug compliance. If the patient is experiencing breakthrough&#xD;
                symptoms, a clinic visit will be required for Visit 3.&#xD;
&#xD;
           All study visits will take approximately two (2) hours and the telephone contact should&#xD;
           take no longer than thirty (30) minutes.&#xD;
&#xD;
           Study Patients will see both the study coordinator and an investigator at every visit.&#xD;
&#xD;
           At the end of study treatment, subjects will be given treatment options; subjects will&#xD;
           have the option of continuing on ropinirole or returning to the use of pramipexole.&#xD;
           Subjects will then return to the care of their primary care physician/neurologist.&#xD;
&#xD;
           USE OF HUMAN SUBJECTS and/or HUMAN DERIVED MATERIALS&#xD;
&#xD;
           SUBJECT CHARACTERISTICS Patients with moderate to severe Restless Legs Syndrome that are&#xD;
           currently taking a stable dose of Pramipexole will be approached during their visit to&#xD;
           the MCG Movement Disorders Clinic and the VA Neurology Clinic and asked to participate&#xD;
           in SWITCH. If it becomes necessary to recruit from outside of MCG/VAMC, all&#xD;
           advertisement materials will be submitted to the HAC for approval prior to use. SWITCH&#xD;
           is a double site study. We plan to enroll a total of 25-30 individuals between the two&#xD;
           sites. Approximately 20 patients will be enrolled at MCG/VAMC.&#xD;
&#xD;
           MANAGING SIDE EFFECTS As with all drugs, the possibility of unforeseeable risks and side&#xD;
           effects exist. The patients will be told of any important new information that might&#xD;
           affect their decision to continue in the study in a timely manner. Their Restless Legs&#xD;
           Syndrome may not improve or may worsen, despite participation. In previous studies,&#xD;
           patients taking ropinirole reported the following side effects to include: nausea,&#xD;
           headache, dizziness, drowsiness, or sleepiness. Individuals taking ropinirole may&#xD;
           experience dizziness, nausea, sweaty or faintness when first standing up from lying&#xD;
           down. Hallucinations (unreal visions, sounds, or sensations) have also been reported in&#xD;
           patients taking ropinirole, especially in elderly patients, patients taking ropinirole&#xD;
           with L-dopa, or patients taking higher amounts of ropinirole. If a patient is taking&#xD;
           L-dopa for Parkinson's disease, ropinirole may worsen some of the side effects of&#xD;
           L-dopa.&#xD;
&#xD;
           Additionally, ropinirole has been associated with sedating effects, including somnolence&#xD;
           and the possibility of falling asleep while engaged in activities of daily living,&#xD;
           including operation of a motor vehicle.&#xD;
&#xD;
           Syncope or symptomatic hypertension may also occur, particularly during initial&#xD;
           treatment or dose titration. Patients should be cautioned against rising rapidly after&#xD;
           sitting or lying down. Because of possible additive effects, it is recommended that&#xD;
           caution be exercised with patients who have sleep disorders or are taking sedating&#xD;
           medications, alcohol, CNS depressants, or medications that increase ropinirole plasma&#xD;
           levels.&#xD;
&#xD;
           Patients should get medical help and contact the study doctor or study staff, if they&#xD;
           have any of these or any other side effects during the study.&#xD;
&#xD;
           If the study doctor considers that it is in the patient's best interest to discontinue a&#xD;
           current medication so that they can enter the study, the patient may experience some&#xD;
           withdrawal symptoms.&#xD;
&#xD;
           The risks and discomforts of blood drawing from a vein include the possibility of pain&#xD;
           or bruising at the site of the blood draw; occasional feelings of lightheadedness; and,&#xD;
           rarely, infection at the site of the blood draw.&#xD;
&#xD;
           Currently, Ropinirole is an FDA approved drug for the treatment of RLS. There are&#xD;
           currently other medications used for the treatment of Restless Legs Syndrome such as&#xD;
           Pramipexole, gabapentin, Sinemet, clonazepam, opiods (pain medications), benzodiazepines&#xD;
           (sleep medications), anticonvulsants (medications to prevent seizures), and iron&#xD;
           therapy. The study doctor will discuss the benefits and risks associated with these&#xD;
           alternatives with each patient.&#xD;
&#xD;
           If a research related event arises, the study team will manage the patient's care. In&#xD;
           the event of an emergency, the research team is available any time, day or night, via&#xD;
           the MCG paging operator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGI-S/CGI-I: (Visits 1, 2, and 4)</measure>
    <time_frame>5 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>IRLS: (Visits 1, 2, and 4)</measure>
    <time_frame>5 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale: (Visits 1, 2, and 4)</measure>
    <time_frame>5 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG: An &quot;ECG&quot; or &quot;electrocardiogram&quot; is a test that measures the electrical activity of the heart. (Visits 1, 2, and 4)</measure>
    <time_frame>5 min</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <description>PO, 0.25mg, 0.50mg, or 0.75mg QHS</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent is obtained&#xD;
&#xD;
          -  Males and/or females; females of childbearing potential, who are not currently&#xD;
             pregnant, must agree to use a medically accepted method of contraception throughout&#xD;
             the study (i.e., oral contraception, intra- uterine device, or a long-acting&#xD;
             injectable form of contraception). Barrier methods alone (i.e., condom) are not&#xD;
             adequate.&#xD;
&#xD;
          -  Age &gt; 18 years to â‰¤ 80 years&#xD;
&#xD;
          -  Patients with moderate to severe primary RLS&#xD;
&#xD;
          -  Stable dose of Pramipexole, between 0.25 mg and 0.75mg, for Restless Legs Syndrome for&#xD;
             4 weeks prior to enrollment&#xD;
&#xD;
          -  IRLS &gt;15 (before pramipexole was initiated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Anyone who does not fit the criteria stated under &quot;Inclusion Criteria&quot; and anyone who is&#xD;
        included in the following criteria:&#xD;
&#xD;
          -  Currently taking neuroleptic medications&#xD;
&#xD;
          -  Currently taking dopamine blocking anti-emetic medications.&#xD;
&#xD;
          -  Currently taking any drug known to substantially inhibit CYP1A2 (e.g., cimetidine,&#xD;
             fluvoxamine) or induce CYP1A2 (e.g., omeprazole) (Note: Subjects already on these&#xD;
             agents may be enrolled, but must remain on stable doses of the agents from (Visit 1)&#xD;
             14 days prior to Baseline to the end of the study.&#xD;
&#xD;
          -  Current hallucinations&#xD;
&#xD;
          -  History of disabling hallucinations or hallucinations in past requiring treatment&#xD;
&#xD;
          -  Mini-Mental status examination score &lt; 25 on a scale of 30&#xD;
&#xD;
          -  Orthostatic hypotension &gt;30 systolic drop and &gt;20 diastolic drop&#xD;
&#xD;
          -  On cholinesterase inhibitors or memantine&#xD;
&#xD;
          -  Troublesome edema due to any reason&#xD;
&#xD;
          -  Epworth sleepiness scale &gt;8&#xD;
&#xD;
          -  Another primary sleep disorder (e.g. obstructive sleep apnea, narcolepsy)&#xD;
&#xD;
          -  Secondary causes of RLS (iron deficiency, renal failure)&#xD;
&#xD;
          -  Unstable medical conditions as determined by the investigator&#xD;
&#xD;
          -  Inadequately managed depression (patient on antidepressants must be on stable dose for&#xD;
             4 weeks prior to enrollment)&#xD;
&#xD;
          -  Other stable medical conditions which may interfere with patient evaluation&#xD;
&#xD;
          -  Female who is pregnant or lactating&#xD;
&#xD;
          -  Use of an investigational drug within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kapil D Sethi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>June 23, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kapil Sethi/ / PI</name_title>
    <organization>Georgia Health Sciences University</organization>
  </responsible_party>
  <keyword>Restless Legs Syndrome</keyword>
  <keyword>Mirapex (pramipexole)</keyword>
  <keyword>Requip(Ropinirole)</keyword>
  <keyword>Dopamine Agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

